Log in using OpenID

Cancer Genome Sequencing Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast 2014 - 2022

Over the last few years, the genomic era of cancer studies is developing at a rapid pace fueled by the emergence of next-generation sequencing technology rendering exquisite resolution and sensitivity. Frequent alterations in their gross chromosomal
Single User License:
Cancer Genome Sequencing Market Global Industry Analysis, Size,
Share, Growth, Trends And Forecast
2014 – 2022
USD 4315.5
Transparency Market Research
State Tower,
90, State Street, Suite 700.
Albany, NY 12207
United States
[email protected]
Flat 10% Discount!!
Free Customization as per your requirement
You will get Custom Report at Syndicated Report
Report will be delivered with in 15-20 working days
Request Sample
Buy Now
Over the last few years, the genomic era of cancer studies is developing at a rapid pace fueled by the
emergence of next-generation sequencing technology rendering exquisite resolution and sensitivity.
Frequent alterations in their gross chromosomal structure by means of amplification, deletion and
inversion of their chromosomal structure forms a characteristic feature of cancer genome. These gene
alterations or modifications ultimately lead to cancer onset and progression.
Browse Full Report with TOC @
Additionally, the gene sequencing for cancer has several advantages over traditional approaches which
include the ability to perform complete gene sequencing in single test including the detecting copy
number alterations, translocations, and exome-wide base substitutions in all related cancer cells. The
reduction in the cost associated with whole genome sequencing and overall time required to perform these
sequencing has drastically reduced in last couple of years. A study published by,
Inc. in 2013 illustrated that five years ago expenses for performing whole genome sequencing were in
millions of dollars which currently can be performed solely for few thousand dollars. Numerous
technological advancements have significantly contributed in advancing the research studies pertaining to
cancer diagnosis and treatment. Despite this the recombinant DNA cloning is still in its infancy and is yet
not competent enough in unraveling the full complexity of the human cell.
In June 2014, a new genome sequencing test developed at Memorial Sloan Kettering known as MSK-IMPACT
made cancer analysis far more comprehensive and can be used on any type of solid tumor, irrespective of
its location in the human body. According to the scientists of Memorial Sloan Kettering, cancer
identification and its predisposition can benefit patients, health practitioners and eventually help in
reducing the morbidity and mortality with respect to cancer. A study by Johns Hopkins scientists published
in April 2015 illustrated that in last few years several hospitals and companies have collaborated to
sequence patient’s tumor in an attempt to personalize therapy for cancer treatment. In addition to
selecting personalized therapies for patients with cancer, sequencing the normal tissue genome can also
increase the overall understanding of cancer, including finding reasons for cancer predisposition due to
germline genome changes.
Regulations pertaining to personalized cancer sequencing are primarily governed by the accreditation of
the laboratories performing the sequencing services and analysis, and also the usage of FDA approved
tests for conducting these tests. Drivers to the cancer genome sequencing encompass comprehensive
view of whole genome, ability to majority of mutations, and eliminating the need for having any prior
knowledge about the patient history and current disease status. Such potential growth attributors are likely
to boost the demand for gene sequencing-based personalized cancer treatment in the near future. High
procedural cost and time consuming interpretation of large datasets are among the key restraints to the
market. An alternative to the whole genome sequencing is the targeted gene sequencing method that is
comparative less costly, with easy results interpretation and high sensitivity for rare clones.
Geographically, the market is studied for four regions; North America, Europe, Asia Pacific and Rest of the
World. North America market includes the United States and Canada which form the major revenue
contributors owing to increasing inclination towards gene therapy-based cancer treatment. The region is
followed by Europe which has also initiated several genome-based studies in cancer. An analysis
conducted by Genomics England Ltd. in 2014, revealed that the U.K. is set to become the world leader in
ground breaking genetic research into cancer and rare diseases post a grant of USD 473.3 million by Prime
Minister of U.K. Asia Pacific and Rest of the World are still in nascent stage owing to the need for high initial
investment on laboratory set-up and conducting research activity. However the APAC market is expected to
grow in the forthcoming years due to availability of skilled and scientific-based manpower, strength in
information technology and its growing economy.
Some of the major companies operating in cancer genome sequencing market include Illumina, Inc.,
Beckman Coulter Genomics, SeqWright, BGI Americas Corporation, Pacific Biosciences, Ambry Genetics,
and Foundation Medicine.
This research report analyzes this market on the basis of its market segments, major geographies, and
current market trends. Geographies analyzed under this research report include
North America
Asia Pacific
Middle East and Africa
Latin America
This report provides comprehensive analysis of
Market growth drivers
Factors limiting market growth
Current market trends
Market structure
Market projections for upcoming years
This report is a complete study of current trends in the market, industry growth drivers, and restraints. It
provides market projections for the coming years. It includes analysis of recent developments in
technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also
includes a review of micro and macro factors essential for the existing market players and new entrants
along with detailed value chain analysis.
Inquiry Before Buying:
Latest Press Release Reports:
Latest Articles Reports:
Read More Reports on Biotechnology Market:
About Us
Transparency Market Research (TMR) is a market intelligence company providing global business research
reports and consulting services. Our exclusive blend of quantitative forecasting and trends analysis
provides forward-looking insights for thousands of decision-makers.
TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources along with
various tools and techniques to gather and analyze information. Our business offerings represent the latest
and the most reliable information which is indispensable for businesses to sustain their competitive edge.
Transparency Market Research
90 State Street,
Suite 700,
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: [email protected]
shekharm18   документов Email
technical documentation
File Size
112 Кб
Пожаловаться на содержимое документа